Published in
Elsevier, Osteoarthritis and Cartilage, 4(27), p. 571-579, 2019
DOI: 10.1016/j.joca.2018.11.002
Links
Tools
Proposed study designs for approval based on a surrogate endpoint and a post-marketing confirmatory study under FDA's accelerated approval regulations for disease modifying osteoarthritis drugs
Journal article published in 2019 by
V. B. Kraus 
,
L. S. Simon,
J. N. Katz ,
T. Neogi ,
D. Hunter ,
A. Guermazi,
M. A. Karsdal
,
L. S. Simon,
J. N. Katz ,
T. Neogi ,
D. Hunter ,
A. Guermazi,
M. A. Karsdal
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 